Soluble ST2 (sST2) biomarker is used for additive risk stratification and prognosis of patients with heart failure (HF). ST2 interacts with IL-33, and IL-33/ST2 system is upregulated in cardiomyocytes and fibroblasts in response to cardiac injury or cardiac stress. ST2, in contrast to BNP and NT-proBNP, is not affected by confounding factors such as age, body mass index, and impaired renal function. Unlike many other cardiac biomarkers, the levels of ST2 alters quickly in response to changes in the patient’s condition, therefore helping physicians to make decisions on an appropriate course of action. Elevated levels of sST2 in acute as well as chronic HF patients are strongly associated with the measures of HF severity and predict both recurrent hospitalization and mortality.
The anti-ST2 antibodies were obtained after immunization of various animal species (mice, rabbits, and rats) with recombinant human ST2. They have been well-characterized and can be used for the development of sensitive and precise immunoassays (see Figure 1A).
In addition, all recommended capture-detection pairs tested in sandwich ELISA platform showed similar or better sensitivity than a commercial ST2 assay (see Figure 1B).
Figure 1. Performance of HyTest anti-ST2 MAbs. A) Representative calibration curve for the ST2 prototype assay (S215-S103 sandwich ELISA, LoD 30 pg/ml). HyTest recombinant human ST2 used as the antigen. B) ST2 concentrations obtained with the S215-S103 prototype immunoassay and a commercial ST2 assay. Correlation coefficient (Pearson) between HyTest prototype assay and commercial ST2 assay was 0.98 indicating excellent correlation between the assays.